Many people with stage II or III colon cancer receive additional, or adjuvant, chemotherapy following surgery. However, clinical trials have shown that this treatment doesn’t improve the chances of survival for every patient. A study published July 25th, 2024 in Cell Reports Medicine identifies and validates a 10-gene biomarker that potentially predicts whether a stage II or III colon cancer patient will benefit from adjuvant chemotherapy.
University of Melbourne unveils design of new AIID building
An artist’s impression of the AIID building, designed by Australian architectural company Wardle and engineered by Aurecon. Credit: The University of Melbourne. The University of
June 20, 2023